Page last updated: 2024-11-06

3,3'-diiodothyronine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3,3'-diiodothyronine: RN given refers to unlabeled cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107564
CHEMBL ID1236140
CHEBI ID45698
SCHEMBL ID935895
MeSH IDM0096732

Synonyms (37)

Synonym
CHEMBL1236140 ,
t2
3,3'-t2
3,3'-diiodothyronine
3,3'-deiodo-thyroxine
alanine, 3-[4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl]-, l- (8ci)
3,3'-diiodo-l-thyronine
4604-41-5
l-tyrosine, o-(4-hydroxy-3-iodophenyl)-3-iodo- (9ci)
l-3,3'-diiodothyronine
o-(4-hydroxy-3-iodophenyl)-3-iodo-l-tyrosine
l-tyrosine, o-(4-hydroxy-3-iodophenyl)-3-iodo-
CHEBI:45698 ,
(2s)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl]propanoic acid
tyrosine, o-(4-hydroxy-3-iodophenyl)-3-iodo-
A826975
bdbm50431469
AKOS015918402
einecs 225-005-7
unii-3l9u2z4602
3l9u2z4602 ,
3,3'-diiodothyronine, l-
(2s)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl)propanoic acid
levothyroxine sodium impurity j [ep impurity]
alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl)-, l-
SCHEMBL935895
mfcd01863378
3,3'-diiodo-l-thyronine (t2), 98% (cp)
DTXSID80196697
(s)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl)propanoic acid
AS-57862
CPCJBZABTUOGNM-LBPRGKRZSA-N
3,3'-diiodo-l-thyronine (t2)
Q27104556
HY-129974
CS-0108953
?o-(4-hydroxy-3-iodophenyl)-3-iodo-l-tyrosine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response effects were seen for the increase of fT4, fT3 and T3."( Effects of small doses of bovine TSH on serum levels of free and total thyroid hormones, their degradation products, and diiodotyrosine.
Benker, G; Meinhold, H; Olbricht, T; Reinwein, D; Splittstösser, C, 1985
)
0.27
"1 mU (ip, daily for 3 days), and there was a linear dose-response thereafter."( Characterization of thyrotropin-induced increase in iodothyronine monodeiodinating activity in mice.
Florsheim, WH; Reggio, R; Wu, SY, 1985
)
0.27
" The dose-response curves of inhibition of binding of (125)I-T(2)S to anti-T(2)S by serial dilutions of ethanol extracts of serum or urine were essentially parallel to the standard curve."( A radioimmunoassay for measurement of 3,3'-diiodothyronine sulfate: Studies in thyroidal and nonthyroidal diseases, pregnancy, and fetal/neonatal life.
Chopra, IJ, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3,3'-diiodothyronine
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proliferating cell nuclear antigenHomo sapiens (human)IC50 (µMol)50.00003.60004.95006.3000AID739861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIProliferating cell nuclear antigenHomo sapiens (human)
base-excision repair, gap-fillingProliferating cell nuclear antigenHomo sapiens (human)
mismatch repairProliferating cell nuclear antigenHomo sapiens (human)
heart developmentProliferating cell nuclear antigenHomo sapiens (human)
translesion synthesisProliferating cell nuclear antigenHomo sapiens (human)
epithelial cell differentiationProliferating cell nuclear antigenHomo sapiens (human)
replication fork processingProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of deoxyribonuclease activityProliferating cell nuclear antigenHomo sapiens (human)
response to estradiolProliferating cell nuclear antigenHomo sapiens (human)
cellular response to UVProliferating cell nuclear antigenHomo sapiens (human)
estrous cycleProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA repairProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA replicationProliferating cell nuclear antigenHomo sapiens (human)
response to cadmium ionProliferating cell nuclear antigenHomo sapiens (human)
cellular response to hydrogen peroxideProliferating cell nuclear antigenHomo sapiens (human)
cellular response to xenobiotic stimulusProliferating cell nuclear antigenHomo sapiens (human)
response to dexamethasoneProliferating cell nuclear antigenHomo sapiens (human)
liver regenerationProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA-directed DNA polymerase activityProliferating cell nuclear antigenHomo sapiens (human)
response to L-glutamateProliferating cell nuclear antigenHomo sapiens (human)
mitotic telomere maintenance via semi-conservative replicationProliferating cell nuclear antigenHomo sapiens (human)
leading strand elongationProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
purine-specific mismatch base pair DNA N-glycosylase activityProliferating cell nuclear antigenHomo sapiens (human)
chromatin bindingProliferating cell nuclear antigenHomo sapiens (human)
damaged DNA bindingProliferating cell nuclear antigenHomo sapiens (human)
protein bindingProliferating cell nuclear antigenHomo sapiens (human)
enzyme bindingProliferating cell nuclear antigenHomo sapiens (human)
nuclear estrogen receptor bindingProliferating cell nuclear antigenHomo sapiens (human)
receptor tyrosine kinase bindingProliferating cell nuclear antigenHomo sapiens (human)
dinucleotide insertion or deletion bindingProliferating cell nuclear antigenHomo sapiens (human)
MutLalpha complex bindingProliferating cell nuclear antigenHomo sapiens (human)
histone acetyltransferase bindingProliferating cell nuclear antigenHomo sapiens (human)
identical protein bindingProliferating cell nuclear antigenHomo sapiens (human)
protein-containing complex bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase processivity factor activityProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionProliferating cell nuclear antigenHomo sapiens (human)
male germ cell nucleusProliferating cell nuclear antigenHomo sapiens (human)
nucleusProliferating cell nuclear antigenHomo sapiens (human)
nuclear laminaProliferating cell nuclear antigenHomo sapiens (human)
nucleoplasmProliferating cell nuclear antigenHomo sapiens (human)
replication forkProliferating cell nuclear antigenHomo sapiens (human)
centrosomeProliferating cell nuclear antigenHomo sapiens (human)
nuclear bodyProliferating cell nuclear antigenHomo sapiens (human)
nuclear replication forkProliferating cell nuclear antigenHomo sapiens (human)
PCNA complexProliferating cell nuclear antigenHomo sapiens (human)
extracellular exosomeProliferating cell nuclear antigenHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexProliferating cell nuclear antigenHomo sapiens (human)
chromatinProliferating cell nuclear antigenHomo sapiens (human)
replisomeProliferating cell nuclear antigenHomo sapiens (human)
PCNA-p21 complexProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID739861Inhibition of human recombinant PCNA interaction with PIP box protein N-5-carboxyfluorescein-SAVLQKKITDYFHPKK after 30 mins by fluorescence polarization assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (53.03)18.7374
1990's19 (28.79)18.2507
2000's5 (7.58)29.6817
2010's7 (10.61)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (7.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (92.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]